Merck (MRK)

Currency in USD
134.30
-3.48(-2.53%)
Real-time Data·
Advertisement
MRK is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
133.32139.17
52 wk Range
93.90156.92
Key Statistics
Prev. Close
137.78
Open
137.73
Day's Range
133.32-139.17
52 wk Range
93.9-156.92
Volume
4.17M
Average Volume (3m)
10.18M
1-Year Change
41.2941%
Book Value / Share
18.20
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MRK Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
161.53
Upside
+20.27%
Members' Sentiments
Bearish
Bullish
ProTips
16 analysts have revised their earnings downwards for the upcoming period

Merck & Company Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

19 Buy
9 Hold
0 Sell
Ratings:
28 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 161.53
(+20.27% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Cantor Fitzgerald
Hold155.00+15.56%-Maintain12/11/2026
DZ Bank
Hold153.00+14.07%-Downgrade03/11/2026
Freedom Broker
Hold140.00+4.38%125.00Maintain02/11/2026
Cantor Fitzgerald
Hold155.00+15.56%145.00Maintain02/11/2026
RBC Capital
Hold140.00+4.38%145.00Maintain30/10/2026

Merck & Company Inc SWOT Analysis


Keytruda's Dominance
Explore Merck's reliance on cancer drug Keytruda, its impressive growth, and the looming patent cliff in 2028 that poses significant revenue challenges
Gardasil Hurdles
Delve into Merck's strategic pause of Gardasil sales in China, impacting 2025 forecasts and raising concerns about inventory management and market dynamics
Pipeline Potential
Learn about Merck's promising pipeline, including TROP2 ADC and KRAS inhibitors, as the company seeks to diversify beyond Keytruda and address future growth
M&A Strategy
Analysts eye Merck's robust balance sheet and M&A potential, with acquisitions in the $1-15 billion range, as key to filling the post-Keytruda revenue gap
Read full SWOT analysis

Merck & Company Inc Earnings Call Summary for Q3/2026

  • Merck Q3 2026: EPS $2.49 vs est. $2.09, revenue $18.1B vs est. $17.3B; shares rose 4.8% to $147.73 in pre-market trading.
  • KEYTRUDA sales up 6% to $8.6B; WINREVAIR surged 94% to $694M; GARDASIL rose 14% to $2B, driving oncology and vaccine growth.
  • Full-year guidance raised: revenue $66.8B-$67.3B, EPS $2.77-$2.82; expects modest 2027 growth despite $2B+ generic headwinds.
  • Management confident in post-KEYTRUDA LOE transition, citing pipeline strength including sac-TMT, intismeran, and WINREVAIR expansion.
  • Operating expenses up 12% to $7.4B on launch investments; $3B share buyback planned for 2026; gross margin held at 81.4%.
Last Updated: 29/10/2026, 15:10
Read Full Transcript

Earnings

Latest Release
29/10/2026
EPS / Forecast
2.49 / 2.09
Revenue / Forecast
18.1B / 17.28B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.99
Dividend Yield
2.47%
Industry Median 2.10%
Annualised payout
3.40
Paid quarterly
5-Years Growth
+5.59%
Growth Streak

Compare MRK to Peers and Sector

Metrics to compare
MRK
Peers
Sector
Relationship
P/E Ratio
135.4x56.4x−0.2x
PEG Ratio
−1.591.070.00
Price/Book
7.4x5.1x2.6x
Price / LTM Sales
4.9x7.4x2.7x
Upside (Analyst Target)
20.9%0.0%69.6%
Fair Value Upside
Unlock−5.3%11.7%Unlock

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo’s deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca’s Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Employees
74000

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
1.08B43.67%148.34B
Other Institutional Investors
922.72M37.43%127.13B
Public Companies & Retail Investors
465.85M18.90%64.18B
Total
2.47B100.00%339.66B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.9.21%226,999,83731,276,038
Vanguard Capital Management, LLC7.11%175,192,48324,138,020

People Also Watch

361.40
PANW
+6.32%
104.89
NBIS
-1.94%
282.38
ABBV
-1.27%
49.04
CRWV
+2.53%
514.14
MSFT
+1.35%

FAQ

What Is the Merck&Co (NYSE: MRK) Share Price Today?

The Merck&Co stock price today is 134.30 USD.

What Stock Exchange Does Merck&Co (MRK) Trade On?

Merck&Co is listed and trades on the New York Stock Exchange.

What Is the Ticker (Stock Symbol) for Merck&Co?

The stock symbol (also called a 'ticker') for Merck&Co is "MRK."

Does Merck&Co Pay Dividends? What’s The Current MRK Dividend Yield?

Yes, MRK Pays Dividends to its Shareholders. The current Merck&Co dividend yield is 2.5%%.

What Is the Current Merck&Co Market Capitalisation?

As of today, Merck&Co (NYSE: MRK) market cap is 330.22B USD.

What Is Merck&Co's (MRK) Earnings Per Share (TTM)?

The Merck&Co EPS is currently 0.99 (Trailing Twelve Months).

When Is the Next Merck&Co Earnings Date?

Merck&Co's next earnings report will be released on 02/02/2027.

Is MRK a Buy or Sell From a Technical Analyst Perspective?

Based on today's Merck&Co moving averages and other technical indicators, the daily buy/sell signal for MRK stock is Strong Sell.

How Many Times Has Merck&Co Stock Split?

Merck&Co has split 5 times. (See the MRK stock split history page for full effective split date and price information.)

How Many Employees Does Merck&Co Have?

Merck&Co has 74000 employees, based on their latest Companies House report.

What is the current trading status of Merck&Co (NYSE: MRK)?

As of 19/11/2026, Merck&Co (MRK) is trading at a share price of 134.30 USD, with a previous close of 137.78 USD. The stock has fluctuated within a day range of 133.32 USD to 139.17 USD, while its 52-week range spans from 93.90 USD to 156.92 USD.

What Is Merck&Co (MRK) Price Target According to Analysts?

The average 12-month price target for Merck&Co is 161.53 USD, with a high estimate of 186 USD and a low estimate of 105 USD. 19 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +20.27% Upside potential.

What Is the MRK Premarket Price?

MRK's last pre-market stock price is 136.30 USD. The pre-market share volume is 27,330.00, and the stock has decreased by -1.48, or -1.07%.

What Is the MRK After Hours Price?

MRK's last after hours stock price is 137.67 USD, the stock has decreased by -0.11, or -0.08%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.